First Nations hepatitis B risks revealed in study
Analysing the C4 hepatitis B strain among Aboriginal and Torres Strait Islander people, researchers from Menzies School of Health Research, found a severe type of liver disease among those living with the infection.
"The things we worry about when people have hepatitis b as a chronic infection, if they get liver damage, which can progress to liver cirrhosis or liver failure and they are also at higher risk of liver cancer," study lead and Menzies Hepatitis B program lead Jane Davies told AAP.
"This C4 sub-genotype, when we looked at it in the lab at the very detailed genetics of it, it looked like it was very aggressive with respect to these two things."
The study confirmed the lab findings by analysing clinical data from more than 780 people across the Northern Territory, Professor Davies said.
She said 22 per cent of people in this cohort had significant liver damage, and 16 per cent of those had cirrhosis, which is severe scarring on the liver, which can cause problems with the organ's functioning.
"We've followed people over time, we've looked at different markers of the virus as part of their clinical care and have confirmed there is significantly high rates of liver damage within the population of Aboriginal and Torres Strait Islander people who have this very specific sub-genotype of chronic hepatitis B," Prof Davies said.
Under current Australian guidelines 25 per cent of the cohort studied are receiving treatment, Prof Davies said.
Researchers explored the potential impact of using World Health Organisation expanded treatment guidelines for people living with C4 hepatitis B.
Prof Davies said under the expanded guidelines half of those not currently being treated would be eligible for treatment.
While expanding the guidelines is a nuanced conversation, Prof Davies said, she believes it is common sense to do everything possible to support healthy liver function for those living with hepatitis B.
"My personal opinion is that we should be treating as many people as we can where there is evidence that we can reduce their risk of progression to liver failure and liver cancer," she said.
"That's where the really crucial question comes - is there evidence in this in this very specific sub-genotype in out setting that we should be immediately rolling out treatment to this more than roughly 50 per cent of people.
"That's definitely a nuances conversation with pros and cons."
The study, representing the latest findings from the Hep B PAST program, which aims to eliminate hepatitis B in the NT, was published in BMC Infectious Diseases.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Advertiser
4 hours ago
- The Advertiser
Pascal's fame stretches Down Under for Fantastic Four
Stars of the upcoming Fantastic Four film have graced Australian shores for its local launch. Actor Pedro Pascal, who plays the stretchy superhero Reed Richards, headlined the promotional event in Sydney for Fantastic Four: First Steps - the third silver-screen incarnation of the comic-book series and first in the Marvel Cinematic Universe. Pascal, star of The Mandalorian and The Last of Us, makes his first appearance leading a superhero movie as his star continues to rise. The first Fantastic Four film in 2005 and its 2007 sequel were commercially successful but received a mixed critical reception, before a 2015 reboot panned by audiences and critics alike. This latest iteration, from TV mini-series WandaVision director Matt Shakman, stars Pascal as Richards - also known as Mister Fantastic - who can stretch any part of his body at will to superhuman lengths. The others in the titular quartet stepping out in Sydney are Vanessa Kirby (Sue Storm/Invisible Woman), Ebon Moss-Bachrach (Ben Grimm/The Thing) and Joseph Quinn (Johnny Storm/Human Torch). Kirby shares an interesting trait with her on-screen persona, with both actor and character sporting baby bumps. In the film, the Four "must defend earth from a ravenous space god called Galactus (Ralph Ineson) and his enigmatic Herald, Silver Surfer (Julia Garner)". The action happens on parallel planet Earth-828 and features elements of 1960s culture and futuristic technology. The return of the Fantastic Four to the silver screen will lead into the 2026 release of the next Avengers film, Avengers: Doomsday, the film's producer and Marvel Studios head Kevin Feige said in June. Fantastic Four: First Steps will be released in Australian cinemas on July 24. Stars of the upcoming Fantastic Four film have graced Australian shores for its local launch. Actor Pedro Pascal, who plays the stretchy superhero Reed Richards, headlined the promotional event in Sydney for Fantastic Four: First Steps - the third silver-screen incarnation of the comic-book series and first in the Marvel Cinematic Universe. Pascal, star of The Mandalorian and The Last of Us, makes his first appearance leading a superhero movie as his star continues to rise. The first Fantastic Four film in 2005 and its 2007 sequel were commercially successful but received a mixed critical reception, before a 2015 reboot panned by audiences and critics alike. This latest iteration, from TV mini-series WandaVision director Matt Shakman, stars Pascal as Richards - also known as Mister Fantastic - who can stretch any part of his body at will to superhuman lengths. The others in the titular quartet stepping out in Sydney are Vanessa Kirby (Sue Storm/Invisible Woman), Ebon Moss-Bachrach (Ben Grimm/The Thing) and Joseph Quinn (Johnny Storm/Human Torch). Kirby shares an interesting trait with her on-screen persona, with both actor and character sporting baby bumps. In the film, the Four "must defend earth from a ravenous space god called Galactus (Ralph Ineson) and his enigmatic Herald, Silver Surfer (Julia Garner)". The action happens on parallel planet Earth-828 and features elements of 1960s culture and futuristic technology. The return of the Fantastic Four to the silver screen will lead into the 2026 release of the next Avengers film, Avengers: Doomsday, the film's producer and Marvel Studios head Kevin Feige said in June. Fantastic Four: First Steps will be released in Australian cinemas on July 24. Stars of the upcoming Fantastic Four film have graced Australian shores for its local launch. Actor Pedro Pascal, who plays the stretchy superhero Reed Richards, headlined the promotional event in Sydney for Fantastic Four: First Steps - the third silver-screen incarnation of the comic-book series and first in the Marvel Cinematic Universe. Pascal, star of The Mandalorian and The Last of Us, makes his first appearance leading a superhero movie as his star continues to rise. The first Fantastic Four film in 2005 and its 2007 sequel were commercially successful but received a mixed critical reception, before a 2015 reboot panned by audiences and critics alike. This latest iteration, from TV mini-series WandaVision director Matt Shakman, stars Pascal as Richards - also known as Mister Fantastic - who can stretch any part of his body at will to superhuman lengths. The others in the titular quartet stepping out in Sydney are Vanessa Kirby (Sue Storm/Invisible Woman), Ebon Moss-Bachrach (Ben Grimm/The Thing) and Joseph Quinn (Johnny Storm/Human Torch). Kirby shares an interesting trait with her on-screen persona, with both actor and character sporting baby bumps. In the film, the Four "must defend earth from a ravenous space god called Galactus (Ralph Ineson) and his enigmatic Herald, Silver Surfer (Julia Garner)". The action happens on parallel planet Earth-828 and features elements of 1960s culture and futuristic technology. The return of the Fantastic Four to the silver screen will lead into the 2026 release of the next Avengers film, Avengers: Doomsday, the film's producer and Marvel Studios head Kevin Feige said in June. Fantastic Four: First Steps will be released in Australian cinemas on July 24. Stars of the upcoming Fantastic Four film have graced Australian shores for its local launch. Actor Pedro Pascal, who plays the stretchy superhero Reed Richards, headlined the promotional event in Sydney for Fantastic Four: First Steps - the third silver-screen incarnation of the comic-book series and first in the Marvel Cinematic Universe. Pascal, star of The Mandalorian and The Last of Us, makes his first appearance leading a superhero movie as his star continues to rise. The first Fantastic Four film in 2005 and its 2007 sequel were commercially successful but received a mixed critical reception, before a 2015 reboot panned by audiences and critics alike. This latest iteration, from TV mini-series WandaVision director Matt Shakman, stars Pascal as Richards - also known as Mister Fantastic - who can stretch any part of his body at will to superhuman lengths. The others in the titular quartet stepping out in Sydney are Vanessa Kirby (Sue Storm/Invisible Woman), Ebon Moss-Bachrach (Ben Grimm/The Thing) and Joseph Quinn (Johnny Storm/Human Torch). Kirby shares an interesting trait with her on-screen persona, with both actor and character sporting baby bumps. In the film, the Four "must defend earth from a ravenous space god called Galactus (Ralph Ineson) and his enigmatic Herald, Silver Surfer (Julia Garner)". The action happens on parallel planet Earth-828 and features elements of 1960s culture and futuristic technology. The return of the Fantastic Four to the silver screen will lead into the 2026 release of the next Avengers film, Avengers: Doomsday, the film's producer and Marvel Studios head Kevin Feige said in June. Fantastic Four: First Steps will be released in Australian cinemas on July 24.
Sydney Morning Herald
7 hours ago
- Sydney Morning Herald
The supermarket ‘antidepressant' in your spice rack
Probiotics and vitamin D were more likely than a placebo to reduce depressive symptoms, while most studies found no effects for Omega-3, according to lead author Rachael Frost, a senior lecturer at Liverpool John Moores University. 'However, St John's Wort and saffron more often showed effects compared to placebo, and similar results to prescription antidepressants,' Frost wrote in an accompanying editorial in Frontiers of Pharmacology. Frost, we should note, is a herbal medicine practitioner herself; the first of many caveats we'll cover on this study. It's not surprising St John's Wort showed a strong effect. A Cochrane review, the gold-standard for scientific evidence, found the flower extract could treat symptoms of depression as effectively as antidepressants back in 2008. Ian Hickie, professor of psychiatry and co-director of health and policy at the University of Sydney's Brain and Mind Centre, said St John's Wort is known to be pharmacologically similar to a weak SSRI (selective serotonin reuptake inhibitor) antidepressant medication. 'It should be seen as a 'medicine' and not simply a natural product,' he says. Hickie noted that many of the other natural interventions weighed up in the review were tested on subclinical depression, not the severe illness conventional antidepressants are aimed at, which is important to consider when interpreting the results. The review also didn't analyse the statistical power of each trial's results, which most modern meta-analyses do, and instead simply collated the number of positive and negative experiments on each substance. That doesn't take us far, particularly because most of the trials included in the review had small sample sizes. So where does that leave us with the claim that saffron, alongside St John's Wort, could be as potent as a prescription antidepressant? A narrow evidence base Eighteen studies on saffron were included in the review. Most found the substance improved people's mood and alleviated depression at least as well as conventional medication. But, reading the studies one by one, something caught my eye: at least half were co-authored by the same researcher. Further, all but one of the studies emerged from a small group of research organisations in Iran. That's not surprising; Iran produces 90 per cent of the world's saffron, so naturally the country's scientists would lead experiments on its therapeutic potential. What it does show, however, is that the experimental landscape for saffron is very concentrated. To be confident that a certain new drug or intervention works, ideally, you want labs across many countries running experiments with a range of settings and participants of different ethnicities. It's safe to say the evidence base, as it stands, is narrow. The one study referenced in the paper completed outside of Iran was an Australian one led by Dr Adrian Lopresti, which found saffron extract could help reduce depressive symptoms in people already taking a pharmaceutical antidepressant. Lopresti, who's the managing director of Clinical Trials Australia, also just published a new paper that marks the largest study to date on saffron and mood, with 202 participants. The trial found 72.3 per cent of participants with depressive symptoms (not clinical depression) taking saffron extract significantly improved compared to 54.3 per cent of people on a placebo. Scientists believe saffron could address chemical issues associated with depression, which include problems with neurotransmitters, high inflammatory blood markers, and low levels of antioxidants. 'Saffron is an anti-inflammatory, it's an antioxidant, and it impacts on neurotransmitters too, so it probably works through those different mechanisms,' Lopresti says. Fine print and industry funding But these Australian studies, too, come with a crucial caveat: they were funded by a biotech company that sells saffron supplements. 'I think what you've got to really do is not hedge your bets on just one single study,' Lopresti says when I ask how people should interpret studies funded by industry. 'Has it been replicated across the world with different research organisations?' Loading Jerome Sarris, professor of integrative mental health at the NICM medical research institute, said it's important to note potential conflicts of interest. But they can be managed in placebo-controlled, double-blind studies – where participants and experimenters don't know who's on the placebo – as long as data is analysed independently of industry. 'Of course, read the fine print, look at the conflict of interest and weigh that up in your own mind. But I would also say universities are pretty good in terms of having safeguards around conflict of interest management,' he says. People considering supplements for mood or mental illness should seek professional health advice. Herbs and other supplements can interact with other medications. St John's Wort, for example, can lead to a potentially life-threatening increase in serotonin when combined with some antidepressants.
The Age
7 hours ago
- The Age
The supermarket ‘antidepressant' in your spice rack
Probiotics and vitamin D were more likely than a placebo to reduce depressive symptoms, while most studies found no effects for Omega-3, according to lead author Rachael Frost, a senior lecturer at Liverpool John Moores University. 'However, St John's Wort and saffron more often showed effects compared to placebo, and similar results to prescription antidepressants,' Frost wrote in an accompanying editorial in Frontiers of Pharmacology. Frost, we should note, is a herbal medicine practitioner herself; the first of many caveats we'll cover on this study. It's not surprising St John's Wort showed a strong effect. A Cochrane review, the gold-standard for scientific evidence, found the flower extract could treat symptoms of depression as effectively as antidepressants back in 2008. Ian Hickie, professor of psychiatry and co-director of health and policy at the University of Sydney's Brain and Mind Centre, said St John's Wort is known to be pharmacologically similar to a weak SSRI (selective serotonin reuptake inhibitor) antidepressant medication. 'It should be seen as a 'medicine' and not simply a natural product,' he says. Hickie noted that many of the other natural interventions weighed up in the review were tested on subclinical depression, not the severe illness conventional antidepressants are aimed at, which is important to consider when interpreting the results. The review also didn't analyse the statistical power of each trial's results, which most modern meta-analyses do, and instead simply collated the number of positive and negative experiments on each substance. That doesn't take us far, particularly because most of the trials included in the review had small sample sizes. So where does that leave us with the claim that saffron, alongside St John's Wort, could be as potent as a prescription antidepressant? A narrow evidence base Eighteen studies on saffron were included in the review. Most found the substance improved people's mood and alleviated depression at least as well as conventional medication. But, reading the studies one by one, something caught my eye: at least half were co-authored by the same researcher. Further, all but one of the studies emerged from a small group of research organisations in Iran. That's not surprising; Iran produces 90 per cent of the world's saffron, so naturally the country's scientists would lead experiments on its therapeutic potential. What it does show, however, is that the experimental landscape for saffron is very concentrated. To be confident that a certain new drug or intervention works, ideally, you want labs across many countries running experiments with a range of settings and participants of different ethnicities. It's safe to say the evidence base, as it stands, is narrow. The one study referenced in the paper completed outside of Iran was an Australian one led by Dr Adrian Lopresti, which found saffron extract could help reduce depressive symptoms in people already taking a pharmaceutical antidepressant. Lopresti, who's the managing director of Clinical Trials Australia, also just published a new paper that marks the largest study to date on saffron and mood, with 202 participants. The trial found 72.3 per cent of participants with depressive symptoms (not clinical depression) taking saffron extract significantly improved compared to 54.3 per cent of people on a placebo. Scientists believe saffron could address chemical issues associated with depression, which include problems with neurotransmitters, high inflammatory blood markers, and low levels of antioxidants. 'Saffron is an anti-inflammatory, it's an antioxidant, and it impacts on neurotransmitters too, so it probably works through those different mechanisms,' Lopresti says. Fine print and industry funding But these Australian studies, too, come with a crucial caveat: they were funded by a biotech company that sells saffron supplements. 'I think what you've got to really do is not hedge your bets on just one single study,' Lopresti says when I ask how people should interpret studies funded by industry. 'Has it been replicated across the world with different research organisations?' Loading Jerome Sarris, professor of integrative mental health at the NICM medical research institute, said it's important to note potential conflicts of interest. But they can be managed in placebo-controlled, double-blind studies – where participants and experimenters don't know who's on the placebo – as long as data is analysed independently of industry. 'Of course, read the fine print, look at the conflict of interest and weigh that up in your own mind. But I would also say universities are pretty good in terms of having safeguards around conflict of interest management,' he says. People considering supplements for mood or mental illness should seek professional health advice. Herbs and other supplements can interact with other medications. St John's Wort, for example, can lead to a potentially life-threatening increase in serotonin when combined with some antidepressants.
